Evoke Pharma, Inc. (EVOK)

US — Healthcare Sector
Peers: PTPI  CPIX  AGRX  PRFX  AQST  ADMP  GHSI  ACRX  EGRX  RGC  PROC  IXHL  DERM  JUPW  AVDL  BFRI  SHPH  AKAN  CPHI 

Automate Your Wheel Strategy on EVOK

With Tiblio's Option Bot, you can configure your own wheel strategy including EVOK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EVOK
  • Rev/Share 4.549
  • Book/Share 2.2919
  • PB 1.6668
  • Debt/Equity 0.0248
  • CurrentRatio 1.553
  • ROIC -1.0832

 

  • MktCap 5702725.0
  • FreeCF/Share -1.5211
  • PFCF -1.471
  • PE -1.9171
  • Debt/Assets 0.0088
  • DivYield 0
  • ROE -1.0192

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

William Hill owner Evoke falls at the first-quarter update
EVOK
Published: March 26, 2025 by: Proactive Investors
Sentiment: Negative

Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025. Results for the past calendar year showed revenues up 3% to £1.75 billion and reported losses before tax more than tripling to £191.4 million from £65.2 million the previous year.

Read More
image for news William Hill owner Evoke falls at the first-quarter update

About Evoke Pharma, Inc. (EVOK)

  • IPO Date 2013-09-25
  • Website https://www.evokepharma.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Matthew J. D'Onofrio MBA
  • Employees 3
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.